ABT 828
Alternative Names: ABT-828Latest Information Update: 16 Mar 2010
At a glance
- Originator Abbott Laboratories
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 21 Aug 2003 Phase-I clinical trials in Solid tumours in USA (unspecified route)
- 14 Aug 2001 Preclinical development for Solid tumours in USA (Unknown route)